PMS9 Biologic Therapy Patterns and Associated Costs in Rheumatoid Arthritis Patients Who Initiated a Tumor Necrosis Factor Antagonist Over Two Years  by Wang, H. et al.
MUSCULAR-SKELETAL DISORDERS – Cost Studies
PMS9
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ANTAGONIST OVER TWO YEARS
Wang H1, Wang Y1, Michael T1, Hopkins B1, Bodoria M2, Sondhi M1, Covington M1
1Sanofi-Aventis, Bridgewater, NJ, USA, 2Sanofi-Aventis, Chilly-Mazarin, France
OBJECTIVES: The primary objective was to examine treatment switching and as-
sociated costs in patients with RA who initiated a TNF antagonist. METHODS:
Patients newly initiated on a TNF antagonist therapy were identified in the US
OptumInsight Impact database. Patients (N4278) had a six-month baseline with
no biologic DMARD use prior to the initiation of etanercept (N1705), adalimumab
(N1249) or infliximab (N1324). The index period was from 2007-2008, and pa-
tients were followed for 24-months. Two–year health care utilization and treat-
ment patterns were examined, focused on drug continuation and switching.
RESULTS: Themajority of patients remained on their initial treatment (etanercept,
N1386 of 1705, 81%; adalimumab, N939 of 1249, 75%; infliximab, N1031 of 1324,
78%). Nearly half of these patients were continuously treated over the 24 month
period without a 90 day gap (etanercept, N651, 47%; adalimumab, N469, 50%;
infliximab, N552, 54%). Over 80% of those who switched did so only once. Most
patients who changed switched to a similar route of administration (65-72% for SC
to SC switchers; 72% for IV to IV switchers). There were no differences in Charlson
Comorbidity Index (CCI), except thosewho switched first to a non-TNF antagonist
(i.e., abatacept, certolizumab pegol or rituximab) had more comorbidities than
their TNF antagonist counterparts (mean CCI of 2.0 versus 2.4 in the 2-year follow-
up, p0.002). Patients who switched had higher total costs than those who did not
switch (p0.001), and those who switched multiple times had significantly higher
total costs than those who switched only once (single-switch mean$59352,
N726; multiple-switch mean$71366, N161, p0.001). CONCLUSIONS: RA pa-
tients who initiate a TNF antagonist and subsequently need to change therapies
incur higher cost, particularly those who switched multiple times. When patients
switched, the initial route of administrationwasmaintained. Consideration should
be given when switching treatment in this patient population.
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THE COST OF HOSPITALISATION FOR KNEE OSTEOARTHRITIS IN FRANCE IN
2010
Taieb C
CREES PFSA, Boulogne, France
OBJECTIVES: Evaluate the cost of hospitalization of knee osteoarthritis patients in
France in 2010.METHODS: For hospital stays (medical, surgery and obstetrics)and
for patients treated under Follow-up care and Rehabilitation (formerly &#x0018;
halfway house&#x0019;), use of the PMSI data. The evaluation we carried out is
based on the last 2 years of available data - 2009 and 2010. RESULTS: In France,
around 85 000 patients are treated yearly in hospital for knee osteoarthritis. They
are made up of 62% women and 38% men, with an average age of 70. The average
hospital stay was 9 days (9.1 average per patient per year). The average annual cost
of hospital treatment for one patient is estimated at around €7700 61% of patients
are then treated with rehabilitation, of which 67% are women. The average age of
these patients is 71. Each patient stayed for an average of 35 days, either full or
partial hospitalization with functional reeducation or medical follow-up treat-
ment. The annual treatment cost of a patient in rehabilitation is estimated at
€6986In total, the average annual cost for all patients treated in hospital (medical/
surgery/obstetrics  rehabilitation) for knee osteoarthritis in 2010 is estimated at
€11,961*. In total, the overall annual cost of one patient treated in hospital (medical/
surgery/obstetrics  rehabilitation) for knee osteoarthritis in 2010 is estimated at
€1322 561 546. CONCLUSIONS: The last study evaluating the cost of osteoarthritis
in France (COART - Le Pen and coll, Revue du rhumatisme, December 2005) reported
127,000 short-stay admissions, 175,000 follow-up and/or rehabilitation treatment
days, and 118,000 knee or hip replacements, the overall cost of hospitalizations is
therefore 820 million euros in 2002. Our evaluation demonstrates that this cost
evaluation is outdated, as the amount is lower than the overall cost of hospitaliza-
tions linked to osteoarthritis of the hip
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THE COST OF HOSPITALIZATION OF HIP OSTEOARTHRITIS PATIENTS IN
FRANCE IN 2010
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OBJECTIVES: Evaluate the cost of hospitalization of hip osteoarthritis patients in
France in 2010.METHODS: For hospital stays (medical, surgery and obstetrics)and
f or patients treated under Follow-up care and Rehabilitation (formerly ’halfway
house’), use of the PMSI data. The evaluation we carried out is based on the last 2
years of available data - 2009 and 2010. RESULTS: In France, around 90,000 patients
are treated every year in hospitals for hip osteoarthritis (figures from 2009/2010).
55% of these patients are female, and 45% are male, with an average age of 70. The
average hospital stay was 9 days (9.5 average per patient per year). The average
annual treatment cost for one patient is estimated at around €7100 44% of patients
are then treated with rehabilitation, of which 66% are women. The average age of
these patients is 73. Each patient stays for an average of 32 days, either full or
partial hospitalization with functional reeducation or medical follow-up treat-
ment. The average annual treatment cost of a patient in rehabilitation is estimated
at around €6593. In total, the annual cost of a patient treated in hospital (hospital
rehabilitation) for hip osteoarthritis in 2010 is estimated at €10,000. In total, the
overall annual cost for all patients undergoing hospital treatment in 2010 is esti-
mated at €1,145,942,911. CONCLUSIONS: The last study evaluating the cost of os-
teoarthritis in France (COART - Le Pen and coll, Revue du rhumatisme, December
2005) reported 127 000 short-stay admissions, 175,000 follow-up and/or rehabilita-
tion treatment days, and 118 000 knee or hip replacements, the overall cost of
hospitalizations is therefore 820 million euros in 2002. Our evaluation demon-
strates that this cost evaluation is outdated, as the amount is lower than the overall
cost of hospitalizations linked to osteoarthritis of the hip.
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NUMBER NEEDED TO TREAT (NNT), COST PER RESPONDER (CPR) AND BUDGET
IMPACT (BI) OF TNF INHIBITORS (TNFI) IN THE TREATMENT OF PSORIATIC
ARTHRITIS (PSA)
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OBJECTIVES: Estimate the NNT, CPR and U.S. BI of TNFi in PsA, using clinical
assumptions from an independent National Institute for Health and Clinical Excel-
lence (NICE) systematic review.METHODS: Comparative data were sourced from a
February 2011 NICE systematic review and Bayesian indirect comparison of adali-
mumab (ADA), etanercept (ETA) and infliximab (IFX) in PsA. Primary outcomes
included Psoriatic Arthritis Response Criteria (PsARC) and Psoriasis Area and Se-
verity Index (PASI) 75% response. NICE adjusted outcomes for each TNFi at 12 or 14
weeks vs a standardized placebo response, within each outcome, and these acute
resultswere projected to 52weeks. Based on this data, this analysis applied biologic
costs from January 2012 Wholesale Acquisition Costs and labeled dosing over 52
weeks to derive NNT, CPR and BI. RESULTS: NICE reported results from six trials,
deemed patient characteristics across trials consistent and assessed quality of all
trials as good. The authors of the independent NICE review stated that across all
outcomes of joint and skin disease at 12weeks, IFXwas associatedwith the highest
probabilities of response. These expected placebo-adjusted response rates were as
follows – PsARC: ADA (33.8%), ETA (46.4%), IFX (54.6%); PASI 75: ADA (43.4%), ETA
(13.3%) and IFX (72.5%). This analysis then derived that 52-week CPRwas lowest for
IFX for all outcomes. Also, for PASI 75, NNT to achieve 100 responders was 230.9,
751.9 and 137.9 for ADA, ETA and IFX respectively, with corresponding annual
biologic costs to achieve 100 responders of $5.75M; $17.69M and $3.33M.
CONCLUSIONS: In this analysis of projected 52 week relative outcomes and ex-
pected biologics costs, the incremental annual budget required to achieve 100 PASI
75 responders would be $2,422,816 or $14,360,355 greater if patients were initiated
on ADA or ETA respectively, instead of IFX.
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OBJECTIVES: Celecoxib and duloxetine are FDA approved medications to treat os-
teoarthritis (OA). The purpose of this study was to evaluate the impact of medica-
tion choice between duloxetine and celecoxib onmedication adherence and direct
health care costs among patients with OA. METHODS: This retrospective cohort
study assessed commercially-insured Marketscan OA patients aged 18-64 years
who initiated duloxetine or celecoxib in 2009. All selected patients had 12 months
continuous enrollment in the pre- and post-index periods, and were grouped into
the duloxetine or celecoxib cohort based on the index agent. The first dispense
date, preceded by no coverage of studymedication in the prior 90 days, was defined
as the index date. Both cohorts were then matched via propensity score. The pro-
pensity scores were calculated based on a logistic regression model adjusting for
demographics, comorbidities, prior health care utilization and costs, and prior
medication history. Medication possession ratio (MPR), proportion of patients with
MPR0.8 and health care costs over the 12-month post-index period were com-
pared between cohorts. RESULTS: The matched sample included 2719 patients in
each group. Both cohorts had a mean age of 53 years, and were mostly females.
Over the 12-month post index period, duloxetine-treated patients had significantly
higherMPR (0.53 vs. 0.37, p0.001) and higher proportion of patients withMPR0.8
(34.6% vs. 14.6%, p0.001) than celecoxib-treated patients. While the total health
care costs over the 12-month post-index period were similar between the two
cohorts ($22,125 vs. $22,108, p0.9834), duloxetine-treated patients had signif-
icantly lower OA-related inpatient ($1,607 vs. $2,694, p0.001) and outpatient
costs ($530 vs. $933, p0.001), compared to celecoxib-treated patients.
CONCLUSIONS: OA patients initiating duloxetine had significantly higher medica-
tion adherence and lower OA-related inpatient and outpatient costs. The results,
however, should be interpretedwith caution due to the observational nature of the
claims database.
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HEALTH CARE COSTS AND OPIOID USE AMONG PATIENTS WITH
OSTEOARTHRITIS INITIATING DULOXETINE VERSUS OTHER TREATMENTS
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OBJECTIVES: To compare direct health care costs and opioid use over a 1-year
period following initiation with duloxetine versus other standard of care (SOC)
treatments among patients with osteoarthritis (OA).METHODS: This retrospective
cohort study assessed commercially-insured Marketscan OA patients aged 18-64
yearswho initiated duloxetine or other treatments (celecoxib, opioids, venlafaxine,
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